Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- iloprost
- tenecteplase
Interactions between your drugs
tenecteplase iloprost
Applies to: tenecteplase, iloprost
MONITOR CLOSELY: Drugs that inhibit platelet function may increase the risk of bleeding when administered prior to, during, or after thrombolytic therapy.
MANAGEMENT: Careful monitoring for signs of bleeding, particularly at arterial puncture wounds, is recommended when thrombolytics are used concurrently or sequentially with antiplatelet agents. Some authorities recommend avoiding the initiation of platelet aggregation inhibitors within the first 24 hours following thrombolysis treatment. Local guidelines and prescribing information for individual thrombolytic drugs should be consulted for further recommendations.
References (8)
- (2001) "Product Information. Ticlid (ticlopidine)." Syntex Laboratories Inc
- (2001) "Product Information. Abbokinase (urokinase)." Abbott Pharmaceutical
- (2001) "Product Information. Activase (alteplase)." Genentech
- (2001) "Product Information. Streptase (streptokinase)." Astra-Zeneca Pharmaceuticals
- (2001) "Product Information. Retavase (reteplase)." Boehringer Mannheim
- (2001) "Product Information. TNKase (tenecteplase)." Genentech
- Harder S, Klinkhardt U (2000) "Thrombolytics: drug interactions of clinical significance." Drug Saf, 23, p. 391-9
- Hirsch J, Dalen J, Guyatt G, American College of Chest Physicians (2001) "The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Physicians." Chest, 119(1 Suppl), 1S-2S
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Cialis
Cialis (tadalafil) increase increases blood flow to a certain area of the body and is used to treat ...
Viagra
Viagra (sildenafil) is used to treat erectile dysfunction or impotence in men. Includes Viagra side ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Adcirca
Adcirca is used to treat pulmonary arterial hypertension. Learn about side effects, interactions ...
Opsumit
Opsumit (macitentan) is used to treat pulmonary arterial hypertension. Includes Opsumit side ...
Revatio
Revatio (sildenafil) is used to treat pulmonary arterial hypertension. Includes Revatio side ...
Adempas
Adempas (riociguat) is used to treat pulmonary hypertension. Includes Adempas side effects ...
Winrevair
Winrevair (sotatercept) is an injectable activin signaling inhibitor that can be self-administered ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.